Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786234 | 1.00 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL1791330 | 1.00 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL18393475 | 1.00 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL344781 | 1.00 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL2586890 | 0.91 | HSD17B10 (0.36) | HSD17B10 | |
| SCHEMBL18007258 | 0.91 | HSD17B10 (0.36) | HSD17B10 | |
| SCHEMBL19468591 | 0.90 | — | — | |
| SCHEMBL2936194 | 0.90 | — | — | |
| SCHEMBL23243035 | 0.88 | — | — | |
| SCHEMBL1966205 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| CN-114075168-A | Pyrazole derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-3120852-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR IMMUNE DISEASES | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20160046609-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | CATALYST BIOSCIENCES, INC. | 2016-02-18 | — | — | US | disclosed |
| US-8604191-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine | TARGACEPT, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2442810-A2 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | Targacept Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8153821-B2 | Compounds | TARGACEPT, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120015983-A1 | Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine | TARGACEPT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110281895-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | TARGACEPT, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110269975-A1 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011112428-A2 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | TARGACEPT, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2364307-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2358670-A2 | Novel compounds | Targacept Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2358705-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | Targacept Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015983-A1 | Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, REN, SRMS | HSD17B10 2402/4885 |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | HSD17B10 576/4885 |
| US-20110269975-A1 | NOVEL COMPOUNDS | CHRNB2, CHRNA2, CHRNA5 | HSD17B10 2946/4885 |
| US-20160046609-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | HSD17B10 2193/4885 |
| US-20110281895-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | HSD17B10 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.